Hamlin Capital Management Boosted Its Abb LTD (ABB) Position, Navidea Biopharmaceuticals (NAVB) Sentiment Is 0.72

June 20, 2017 - By Darrin Black

Hamlin Capital Management Llc increased Abb Ltd (ABB) stake by 4.78% reported in 2016Q4 SEC filing. Hamlin Capital Management Llc acquired 147,476 shares as Abb Ltd (ABB)’s stock rose 9.90%. The Hamlin Capital Management Llc holds 3.23M shares with $68.05 million value, up from 3.08M last quarter. Abb Ltd now has $56.97B valuation. The stock increased 0.55% or $0.14 during the last trading session, reaching $25.5. About 14,000 shares traded. ABB Ltd (ADR) (NYSE:ABB) has risen 23.97% since June 20, 2016 and is uptrending. It has outperformed by 7.27% the S&P500.

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical firm focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company has market cap of $80.75 million. The Firm is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. It currently has negative earnings. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages.

Hamlin Capital Management Llc decreased Westrock Co stake by 14,792 shares to 1.01 million valued at $51.11M in 2016Q4. It also reduced General Mtrs Co (NYSE:GM) stake by 253,483 shares and now owns 2.22M shares. Garmin Ltd (NASDAQ:GRMN) was reduced too.

Among 14 analysts covering ABB Ltd (NYSE:ABB), 7 have Buy rating, 2 Sell and 5 Hold. Therefore 50% are positive. ABB Ltd had 27 analyst reports since August 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, February 8 by Natixis. The rating was upgraded by Robert W. Baird on Monday, December 12 to “Outperform”. The rating was upgraded by HSBC on Friday, August 21 to “Buy”. The rating was maintained by Robert W. Baird on Wednesday, October 5 with “Neutral”. Barclays Capital maintained the shares of ABB in report on Wednesday, December 9 with “Overweight” rating. The rating was upgraded by JP Morgan to “Neutral” on Wednesday, April 20. On Tuesday, September 22 the stock rating was downgraded by JP Morgan to “Underweight”. The company was maintained on Friday, March 24 by Morgan Stanley. The stock has “Underperform” rating by BNP Paribas on Tuesday, February 9. The stock of ABB Ltd (ADR) (NYSE:ABB) earned “Sell” rating by Berenberg on Friday, September 4.

Spark Investment Management Llc holds 0.02% of its portfolio in Navidea Biopharmaceuticals Inc for 420,000 shares. Bridgeway Capital Management Inc owns 649,880 shares or 0.01% of their US portfolio. Moreover, Lifeplan Financial Group Inc has 0.01% invested in the company for 28,810 shares. The New York-based Two Sigma Securities Llc has invested 0.01% in the stock. A.R.T. Advisors Llc, a New York-based fund reported 51,700 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: